Catalyst Pharmaceuticals, Inc. (CPRX) Shares Bought by Royal Bank of Canada

Royal Bank of Canada increased its holdings in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 0.0% in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 165,041 shares of the biopharmaceutical company’s stock after buying an additional 41 shares during the quarter. Royal Bank of Canada owned about 0.20% of Catalyst Pharmaceuticals worth $455,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Geode Capital Management LLC increased its holdings in Catalyst Pharmaceuticals by 0.3% in the 1st quarter. Geode Capital Management LLC now owns 462,677 shares of the biopharmaceutical company’s stock worth $902,000 after buying an additional 1,446 shares in the last quarter. Bank of New York Mellon Corp increased its holdings in Catalyst Pharmaceuticals by 3.6% in the 1st quarter. Bank of New York Mellon Corp now owns 69,176 shares of the biopharmaceutical company’s stock worth $135,000 after buying an additional 2,404 shares in the last quarter. Vanguard Group Inc. increased its holdings in Catalyst Pharmaceuticals by 0.5% in the 1st quarter. Vanguard Group Inc. now owns 3,007,935 shares of the biopharmaceutical company’s stock worth $5,865,000 after buying an additional 15,600 shares in the last quarter. OxFORD Asset Management LLP increased its holdings in Catalyst Pharmaceuticals by 46.2% in the 2nd quarter. OxFORD Asset Management LLP now owns 86,168 shares of the biopharmaceutical company’s stock worth $238,000 after buying an additional 27,228 shares in the last quarter. Finally, Nationwide Fund Advisors bought a new stake in Catalyst Pharmaceuticals in the 2nd quarter worth about $111,000. Institutional investors own 40.19% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Catalyst Pharmaceuticals, Inc. (CPRX) Shares Bought by Royal Bank of Canada” was posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are viewing this report on another publication, it was stolen and republished in violation of United States & international copyright and trademark laws. The correct version of this report can be viewed at https://www.chaffeybreeze.com/2017/11/14/catalyst-pharmaceuticals-inc-cprx-shares-bought-by-royal-bank-of-canada.html.

In other news, insider Patrick J. Mcenany bought 20,000 shares of the company’s stock in a transaction on Tuesday, September 5th. The shares were acquired at an average cost of $2.58 per share, with a total value of $51,600.00. Following the completion of the transaction, the insider now owns 4,471,026 shares of the company’s stock, valued at approximately $11,535,247.08. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Company insiders own 8.79% of the company’s stock.

Catalyst Pharmaceuticals, Inc. (NASDAQ CPRX) opened at $2.93 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $1.01 and a 12-month high of $3.24.

Several equities research analysts recently commented on CPRX shares. Piper Jaffray Companies set a $6.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, August 7th. Roth Capital set a $5.00 price objective on Catalyst Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, August 10th. SunTrust Banks, Inc. reissued a “buy” rating and issued a $5.00 target price on shares of Catalyst Pharmaceuticals in a research report on Tuesday, September 5th. Zacks Investment Research cut Catalyst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 11th. Finally, HC Wainwright reissued a “buy” rating and issued a $6.00 target price on shares of Catalyst Pharmaceuticals in a research report on Friday. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $5.50.

Catalyst Pharmaceuticals Company Profile

Catalyst Pharmaceuticals, Inc, formerly Catalyst Pharmaceutical Partners, Inc, is a development-stage biopharmaceutical company. The Company is focused on developing and commercializing therapies for people with rare debilitating diseases. The Company has three drugs in development: Firdapse, CPP-109 and CPP-115.

Institutional Ownership by Quarter for Catalyst Pharmaceuticals (NASDAQ:CPRX)

Receive News & Ratings for Catalyst Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply